101 related articles for article (PubMed ID: 6311322)
1. Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.
Woodman CB; Buchan A; Fuller A; Hartley C; Skinner GR; Stocker D; Sugrue D; Clay JC; Wilkins G; Wiblin C
Br J Vener Dis; 1983 Oct; 59(5):311-3. PubMed ID: 6311322
[TBL] [Abstract][Full Text] [Related]
2. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis.
Skinner GR; Woodman C; Hartley C; Buchan A; Fuller A; Wiblin C; Wilkins G; Melling J
Dev Biol Stand; 1982; 52():333-44. PubMed ID: 6299842
[TBL] [Abstract][Full Text] [Related]
3. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.
Skinner GR; Woodman CB; Hartley CE; Buchan A; Fuller A; Durham J; Synnott M; Clay JC; Melling J; Wiblin C; Wilkins J
Br J Vener Dis; 1982 Dec; 58(6):381-6. PubMed ID: 6293640
[TBL] [Abstract][Full Text] [Related]
4. Control of herpes simplex virus infections of the genital tract by vaccination.
Buchan A; Skinner GR; Fuller A; Hartley C; Hallworth J; Stocker D; Melling J; Wiblin C
Vaccine; 1985 Mar; 3(1):49-53. PubMed ID: 4002836
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial.
Skinner GR; Turyk ME; Benson CA; Wilbanks GD; Heseltine P; Galpin J; Kaufman R; Goldberg L; Hartley CE; Buchan A
Med Microbiol Immunol; 1997 Jun; 186(1):31-6. PubMed ID: 9255764
[TBL] [Abstract][Full Text] [Related]
6. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.
Skinner GR; Fink C; Melling J; Wiblin C; Thornton B; Hallworth J; Gardner W; McLeish P; Hartley C; Buchan A
Med Microbiol Immunol; 1992; 180(6):305-20. PubMed ID: 1549071
[TBL] [Abstract][Full Text] [Related]
7. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.
Skinner GR; Fink CG; Cowan M; Buchan A; Fuller A; Hartley CE; Durham J; Wiblin C; Melling J
Med Microbiol Immunol; 1987; 176(3):161-8. PubMed ID: 3037289
[TBL] [Abstract][Full Text] [Related]
8. Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK): preliminary clinical evidence.
Skinner GR; Davies JA; Dundarov S; Andonov P
Croat Med J; 2000 Dec; 41(4):378-83. PubMed ID: 11063759
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model.
Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR
Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107
[TBL] [Abstract][Full Text] [Related]
10. Prevention of type 2 herpes simplex virus induced cervical carcinoma in mice by prior immunization with a vaccine prepared from type 1 herpes simplex virus.
Chen MH; Dong CY; Liu ZH; Skinner GR; Hartley CE
Vaccine; 1983 Dec; 1(1):13-6. PubMed ID: 6099637
[TBL] [Abstract][Full Text] [Related]
11. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes.
Douglas JM; Vontver LA; Stamm WE; Reeves WC; Critchlow C; Remington ML; Holmes KK; Corey L
Antimicrob Agents Chemother; 1985 Feb; 27(2):203-6. PubMed ID: 3885848
[TBL] [Abstract][Full Text] [Related]
12. Does circumcision influence recurrences in herpes genitalis?
Jerath VP; Mahajan VK
Indian J Dermatol Venereol Leprol; 2009; 75(6):575-8. PubMed ID: 19915236
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.
Skinner GR; Buchan A; Williams D; Marsden J; Hartley C; Wilbanks G; Turyk M; Namkoong ES
Br J Exp Pathol; 1982 Aug; 63(4):378-87. PubMed ID: 6295430
[TBL] [Abstract][Full Text] [Related]
14. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
15. Acyclovir suppression to prevent recurrent genital herpes at delivery.
Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD
Infect Dis Obstet Gynecol; 2002; 10(2):71-7. PubMed ID: 12530483
[TBL] [Abstract][Full Text] [Related]
16. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.
Casanova G; Cancela R; Alonzo L; Benuto R; Magana Mdel C; Hurley DR; Fishbein E; Lara C; Gonzalez T; Ponce R; Burnett JW; Calton GJ
Cutis; 2002 Oct; 70(4):235-9. PubMed ID: 12403316
[TBL] [Abstract][Full Text] [Related]
17. Genital herpes.
Nilsen A
Scand J Infect Dis Suppl; 1985; 47():51-7. PubMed ID: 3006234
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
[TBL] [Abstract][Full Text] [Related]
19. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial.
Scott LL; Hollier LM; McIntire D; Sanchez PJ; Jackson GL; Wendel GD
Infect Dis Obstet Gynecol; 2001; 9(2):75-80. PubMed ID: 11495557
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of herpes genitalis in university women].
Suárez M; Briones H; Alarcón G; Aliaga P; Del Solar E; Grunberg A; de Diego S
Rev Med Chil; 1991 Apr; 119(4):418-22. PubMed ID: 1668822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
